RB-312 / Refuge Biotech - LARVOL DELTA

Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment. (PubMed, J Transl Med) - "RB-312, the first clinically relevant product incorporating a CRISPRa system with non-gene editing and reversible upregulation of endogenous gene expression that promotes CAR-T cells persistence and effectiveness against HER2-expressing tumors. The autocrine effects of reversible, nanoscale IL-12 production limits the risk of off-tumor leakage and systemic toxicity."

CAR T-Cell Therapy • IO biomarker • Journal • Head and Neck Cancer • Hematological Disorders • Hematological Malignancies • Immune Modulation • Oncology • Oropharyngeal Cancer • Solid Tumor • IL12A • RELA